EP4477231A3 - Kombinationsimpfstoff - Google Patents
Kombinationsimpfstoff Download PDFInfo
- Publication number
- EP4477231A3 EP4477231A3 EP24199040.7A EP24199040A EP4477231A3 EP 4477231 A3 EP4477231 A3 EP 4477231A3 EP 24199040 A EP24199040 A EP 24199040A EP 4477231 A3 EP4477231 A3 EP 4477231A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- combination vaccine
- antigenic function
- protein
- vaccine
- hemagglutinin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940001442 combination vaccine Drugs 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 101710154606 Hemagglutinin Proteins 0.000 abstract 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 4
- 101710176177 Protein A56 Proteins 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 4
- 239000000185 hemagglutinin Substances 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000712464 Orthomyxoviridae Species 0.000 abstract 1
- 241000711504 Paramyxoviridae Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2013002513 | 2013-08-21 | ||
| EP14761282.4A EP3035959A1 (de) | 2013-08-21 | 2014-08-21 | Kombinationsimpfstoff |
| PCT/EP2014/002302 WO2015024669A1 (en) | 2013-08-21 | 2014-08-21 | Combination vaccine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14761282.4A Division EP3035959A1 (de) | 2013-08-21 | 2014-08-21 | Kombinationsimpfstoff |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4477231A2 EP4477231A2 (de) | 2024-12-18 |
| EP4477231A3 true EP4477231A3 (de) | 2025-03-19 |
Family
ID=56024444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14761282.4A Withdrawn EP3035959A1 (de) | 2013-08-21 | 2014-08-21 | Kombinationsimpfstoff |
| EP24199040.7A Pending EP4477231A3 (de) | 2013-08-21 | 2014-08-21 | Kombinationsimpfstoff |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14761282.4A Withdrawn EP3035959A1 (de) | 2013-08-21 | 2014-08-21 | Kombinationsimpfstoff |
Country Status (1)
| Country | Link |
|---|---|
| EP (2) | EP3035959A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| WO2021239880A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012116811A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| WO2000035481A2 (en) | 1998-12-17 | 2000-06-22 | Connaught Laboratories Limited | Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation |
| DE102006060799A1 (de) | 2006-12-21 | 2008-06-26 | RUHR-UNIVERSITäT BOCHUM | RSV F-Protein und seine Verwendung |
| JP5796011B2 (ja) | 2009-06-24 | 2015-10-21 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
-
2014
- 2014-08-21 EP EP14761282.4A patent/EP3035959A1/de not_active Withdrawn
- 2014-08-21 EP EP24199040.7A patent/EP4477231A3/de active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012116811A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
Non-Patent Citations (6)
| Title |
|---|
| BENJAMIN PETSCH ET AL: "Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection", NATURE BIOTECHNOLOGY, vol. 30, no. 12, 1 January 2012 (2012-01-01), pages 1210 - 1216, XP055051005, ISSN: 1087-0156, DOI: 10.1038/nbt.2436 * |
| C. JOHNSTONE: "Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus", JOURNAL OF GENERAL VIROLOGY, vol. 85, no. 11, 1 November 2004 (2004-11-01), pages 3229 - 3238, XP055560081, ISSN: 0022-1317, DOI: 10.1099/vir.0.80219-0 * |
| ELIZABETH AGENBACH ET AL: "Amino Acid Variation within the Fusion Protein of Respiratory Syncytial Virus Subtype A and B Strains during Annual Epidemics in South Africa", VIRUS GENES., vol. 30, no. 2, 1 March 2005 (2005-03-01), US, pages 267 - 278, XP055560344, ISSN: 0920-8569, DOI: 10.1007/s11262-004-5633-2 * |
| FLEETON M N ET AL: "Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 183, no. 9, 1 May 2001 (2001-05-01), pages 1395 - 1398, XP002224503, ISSN: 0022-1899, DOI: 10.1086/319857 * |
| S. DE BAETS ET AL: "Recombinant Influenza Virus Carrying the Respiratory Syncytial Virus (RSV) F85-93 CTL Epitope Reduces RSV Replication in Mice", JOURNAL OF VIROLOGY, vol. 87, no. 6, 9 January 2013 (2013-01-09), pages 3314 - 3323, XP055148479, ISSN: 0022-538X, DOI: 10.1128/JVI.03019-12 * |
| TALAAT A M ET AL: "A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses", VACCINE, ELSEVIER LTD, GB, vol. 20, no. 3-4, 12 November 2001 (2001-11-12), pages 538 - 544, XP027321869, ISSN: 0264-410X, [retrieved on 20011112] * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4477231A2 (de) | 2024-12-18 |
| EP3035959A1 (de) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014310935B2 (en) | Combination vaccine | |
| EP4233898A3 (de) | Influenza-mrna-impfstoffe | |
| JOP20200091A1 (ar) | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري | |
| PH12013501683A1 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| MX369469B (es) | Vacuna contra el virus respiratorio sincitial. | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| WO2012024632A3 (en) | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus m2e | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| PL408649A1 (pl) | Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy | |
| WO2014152946A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| BR112015023738A2 (pt) | vacinas de nucleoproteina influenza | |
| EP4477231A3 (de) | Kombinationsimpfstoff | |
| PH12014500369A1 (en) | Influenza h5 vaccines | |
| WO2010127252A3 (en) | Monoclonal antibodies to influenza h1n1 virus and uses thereof | |
| EA201592298A1 (ru) | Полуживая вирусная вакцина против респираторно-синцитиального вируса | |
| WO2012058493A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
| WO2013173256A3 (en) | New and improved influenza vaccines | |
| MX2015010763A (es) | Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento. | |
| EA201592299A1 (ru) | Полуживая вирусная вакцина против респираторно-синцитиального вируса | |
| PH12012502273A1 (en) | Marker vaccine for classical swine fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240906 |
|
| AC | Divisional application: reference to earlier application |
Ref document number: 3035959 Country of ref document: EP Kind code of ref document: P |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0039155000 Ipc: A61K0039120000 |
|
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/16 20060101ALI20250211BHEP Ipc: A61P 31/14 20060101ALI20250211BHEP Ipc: A61K 39/12 20060101AFI20250211BHEP |